Thoratec Corp. is counting on its future product pipeline, especially HeartMate III and HeartMate PHP, to drive revenue growth in its struggling flagship HeartMate ventricular assist device business.
On August 6, the company reported $118.1 million in revenue for the second quarter of 2014, a year-over-year drop of 9.5 percent, mostly due to declining sales of the HeartMate II VAD
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?